NEW YORK, February 03, 2025--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE ... today announced it has initiated an Expanded Access Program (EAP) for taletrectinib in the U.S. for the treatment of ...
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced it has initiated an Expanded Access ...